Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BEAM 
Beam Therapeutics Inc (BEAM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: BEAM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $45.92
1 Year Target Price $45.92
| 10 | Strong Buy |
| 4 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -46% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.32B USD | Price to earnings Ratio - | 1Y Target Price 45.92 |
Price to earnings Ratio - | 1Y Target Price 45.92 | ||
Volume (30-day avg) 17 | Beta 2.15 | 52 Weeks Range 13.53 - 35.25 | Updated Date 09/17/2025 |
52 Weeks Range 13.53 - 35.25 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.5 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1419.22% |
Management Effectiveness
Return on Assets (TTM) -21.02% | Return on Equity (TTM) -41.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1322088015 | Price to Sales(TTM) 38.45 |
Enterprise Value 1322088015 | Price to Sales(TTM) 38.45 | ||
Enterprise Value to Revenue 21.94 | Enterprise Value to EBITDA -7.03 | Shares Outstanding 101162000 | Shares Floating 87015185 |
Shares Outstanding 101162000 | Shares Floating 87015185 | ||
Percent Insiders 1.19 | Percent Institutions 105.18 |
Upturn AI SWOT
Beam Therapeutics Inc
Company Overview
History and Background
Beam Therapeutics was founded in 2017 and is a biotechnology company pioneering precision genetic medicines through base editing. The company aims to develop life-long cures for patients suffering from serious diseases.
Core Business Areas
- Base Editing Therapeutics: Development of novel base editing technologies to precisely edit single base pairs in DNA and RNA. This includes therapeutic applications in various diseases such as genetic disorders, cancer, and infectious diseases.
- Drug Discovery and Development: Research and development of novel base editing therapeutic candidates, from early-stage discovery to clinical trials.
- Manufacturing and Technology Platform: Developing and refining the technology platform required for the manufacture and delivery of base editing therapeutics.
Leadership and Structure
John Evans, CEO; Giuseppe Ciaramelli, Chief Financial Officer; The company has a board of directors and operates with a focus on research, development, and clinical programs.
Top Products and Market Share
Key Offerings
- BEAM-101 (Sickle Cell Disease): An investigational base editing therapy for sickle cell disease. It aims to increase fetal hemoglobin production. It is currently in clinical trials. Competitors include CRISPR Therapeutics (CRSP), Vertex Pharmaceuticals (VRTX) with Casgevy, and bluebird bio (BLUE) with gene therapies.
- BEAM-201 (T-cell Acute Lymphoblastic Leukemia): An investigational base editing therapy for T-cell acute lymphoblastic leukemia. It is currently in clinical trials. Competitors include Novartis (NVS) and Kite Pharma (GILD) for CAR-T therapies.
- BEAM-302 (Alpha-1 Antitrypsin Deficiency): An investigational base editing therapy for Alpha-1 antitrypsin deficiency. It is in preclinical development. Competitors include Vertex Pharmaceuticals (VRTX) and Takeda (TAK).
Market Dynamics
Industry Overview
The gene editing industry is rapidly growing, with significant investments and advancements in technologies such as CRISPR, base editing, and prime editing. The market is driven by the potential to cure genetic diseases and develop personalized medicines.
Positioning
Beam Therapeutics is a leader in base editing technology, positioning itself as a pioneer in precision genetic medicines. Its competitive advantage lies in its proprietary base editing platform and expertise.
Total Addressable Market (TAM)
The total addressable market (TAM) for gene editing therapies is expected to reach billions of dollars within the next decade. Beam Therapeutics is positioned to capture a significant portion of this market through its base editing technology and therapeutic pipeline. Estimates suggest the gene editing market will be at least $15B by 2030. It is positioned well, but there are a lot of strong competitors.
Upturn SWOT Analysis
Strengths
- Proprietary base editing technology
- Strong intellectual property portfolio
- Experienced leadership team
- Advanced therapeutic pipeline
- Strategic partnerships
Weaknesses
- Early stage of development
- High research and development costs
- Clinical trial risks
- Dependence on key personnel
Opportunities
- Expanding therapeutic pipeline
- Strategic collaborations and partnerships
- Advancements in delivery technologies
- Regulatory approvals for base editing therapies
- Addressing unmet medical needs
Threats
- Competition from other gene editing technologies
- Regulatory hurdles
- Intellectual property disputes
- Ethical concerns
- Unfavorable clinical trial outcomes
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- NTLA
Competitive Landscape
Beam Therapeutics has a competitive advantage in base editing technology. However, it faces competition from other gene editing companies with different technology platforms and therapeutic pipelines.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D progress, clinical trial initiations, and strategic collaborations.
Future Projections: Future growth is dependent on clinical trial successes, regulatory approvals, and commercialization of base editing therapies. Analysts project significant revenue growth in the long term.
Recent Initiatives: Recent initiatives include advancing clinical trials for BEAM-101 and BEAM-201, expanding the therapeutic pipeline, and establishing strategic partnerships.
Summary
Beam Therapeutics is a pioneering gene-editing company with promising base editing technology. While still in the early stages of development, the company's strong IP, experienced leadership, and strategic partnerships provide a solid foundation. Clinical trial risks and competition remain key challenges, but potential regulatory approvals could drive significant long-term growth. Overall, Beam Therapeutics exhibits strong potential within the rapidly evolving gene-editing landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Beam Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2020-02-06 | CEO & Director Mr. John M. Evans M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 509 | Website https://beamtx.com |
Full time employees 509 | Website https://beamtx.com | ||
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.